What Biobot Surgical does
Biobot Surgical builds the Mona Lisa robotic platform, which fuses MRI and ultrasound imaging with AI-based prostate segmentation and automated needle-trajectory planning to guide targeted prostate biopsies and focal ablation. The company says Mona Lisa has been deployed in around 50 units worldwide and used in more than 20,000 procedures, and holds regulatory clearances in the US (FDA), Europe (CE), Australia (TGA) and Singapore (HSA). Hospitals and urologists are the primary users. The company says the new funding will expand adoption of Mona Lisa, strengthen its clinical evidence base and build commercial capabilities in overseas markets, particularly the US.
Biobot Surgical is a healthcare tool on Falcoscan. AI-guided robotic platform for prostate cancer biopsy and ablation. Falcoscan rates Biobot Surgical with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: hot. Biobot Surgical is founded in 2017, currently at Series_c stage. Pricing: Paid.